BR9914256A - Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr) - Google Patents

Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)

Info

Publication number
BR9914256A
BR9914256A BR9914256-2A BR9914256A BR9914256A BR 9914256 A BR9914256 A BR 9914256A BR 9914256 A BR9914256 A BR 9914256A BR 9914256 A BR9914256 A BR 9914256A
Authority
BR
Brazil
Prior art keywords
formula
rxr
retinoid
receptors
acid derivatives
Prior art date
Application number
BR9914256-2A
Other languages
English (en)
Inventor
Vidyasagar Vuligonda
Kwok Yin Tsang
Jayasree Vasudevan
Roshantha A Chandraratna
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of BR9914256A publication Critical patent/BR9914256A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE áCIDO 2,4-PENTADIENóICO TENDO ATIVIDADE SELETIVA PARA RECEPTORES DE RETINóIDE X (RXR)"<D>. Compostos da <B>Fórmula (1), Fórmula (2)<D> ou <B>Fórmula (3)<D> onde <B>X<D> é O, S ou (C<B>R~ 1~R~ 1~<D>)~ n~ onde n é 0, 1 ou 2; Y é um radical bivalente tendo a <B>Fórmula (4)<D> ou a <B>Fórmula (5)<D>, onde <B>o<D> é um número inteiro de 1 a 4 ou Y é uma radical arila bivalente ou heteroarila de 5 ou 6 elementos tendo 1 a 3 heteroátomos selecinados de N, S e O, os referidos grupos arila e heteroarila sendo não-substituídos ou substituídos por 1 a 3 grupos C~ 1-6~ alquila ou por 1 a 3 C~ 1-6~ fluoroalquila; e os símbolos restantes possuem o significado descrito na especificação, possuem atividade semelhantes aos agonistas seletivos de retinóide RXR.
BR9914256-2A 1998-10-01 1999-09-20 Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr) BR9914256A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,950 US6147224A (en) 1998-10-01 1998-10-01 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
PCT/US1999/021712 WO2000020370A1 (en) 1998-10-01 1999-09-20 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors

Publications (1)

Publication Number Publication Date
BR9914256A true BR9914256A (pt) 2001-07-03

Family

ID=22596791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914256-2A BR9914256A (pt) 1998-10-01 1999-09-20 Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)

Country Status (17)

Country Link
US (1) US6147224A (pt)
EP (2) EP1117628B1 (pt)
JP (1) JP2002526516A (pt)
KR (2) KR20010075457A (pt)
CN (1) CN1328538A (pt)
AR (1) AR020691A1 (pt)
AT (1) ATE254593T1 (pt)
AU (1) AU757932B2 (pt)
BR (1) BR9914256A (pt)
CA (1) CA2346034A1 (pt)
DE (1) DE69912973T2 (pt)
ES (1) ES2207339T3 (pt)
HK (1) HK1039477A1 (pt)
NZ (1) NZ510528A (pt)
TW (1) TW580494B (pt)
WO (1) WO2000020370A1 (pt)
ZA (1) ZA200102635B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
AU778655B2 (en) 1999-08-27 2004-12-16 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2442366C (en) * 2001-03-27 2012-09-25 Circagen Pharmaceutical, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6388105B1 (en) * 2001-09-27 2002-05-14 Allergan Sales, Inc. Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
EP1511477A4 (en) 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
US6683092B1 (en) 2003-04-09 2004-01-27 Allergan, Inc. [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
DK1937244T3 (en) * 2005-09-30 2018-10-29 Io Therapeutics Llc : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
CA2858882C (en) 2011-12-13 2021-02-02 Trustees Of Dartmouth College Autoimmune disorder treatment using rxr agonists
CN105308026B (zh) * 2013-07-09 2018-12-21 东曹株式会社 具有金刚烷基的环状吖嗪化合物、制造方法、以及以该化合物作为构成成分的有机电致发光元件
KR102489706B1 (ko) 2015-10-31 2023-01-17 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
PL3426303T3 (pl) 2016-03-10 2022-10-03 Io Therapeutics, Inc. Leczenie zaburzeń mięśniowych za pomocą kombinacji agonistów rxr i hormonów tarczycy
KR102605349B1 (ko) 2016-03-10 2023-11-22 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
CN111465402B (zh) * 2017-11-17 2022-05-24 Io治疗公司 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826760D0 (en) * 1988-11-16 1988-12-21 Wellcome Found Pesticides
EP0617614B1 (en) * 1991-12-18 1998-03-04 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
ATE195716T1 (de) * 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
CA2153236A1 (en) * 1993-01-11 1995-02-09 Marcus F. Boehm Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
WO1996005165A1 (en) * 1994-08-10 1996-02-22 F. Hoffmann-La Roche Ag Retinoic acid x-receptor ligands
IL116259A (en) * 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
AU726450B2 (en) * 1995-10-06 2000-11-09 Ligand Pharmaceuticals Incorporated Dimer-selective RXR modulators and methods for their use
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
BR9917205A (pt) * 1999-03-08 2001-12-26 Basilea Pharmaceutica Ag Antagonistas de retinóides e seu uso

Also Published As

Publication number Publication date
CN1328538A (zh) 2001-12-26
DE69912973D1 (de) 2003-12-24
EP1117628B1 (en) 2003-11-19
AR020691A1 (es) 2002-05-22
HK1039477A1 (en) 2002-04-26
NZ510528A (en) 2003-04-29
KR20010075457A (ko) 2001-08-09
EP1388534A2 (en) 2004-02-11
AU757932B2 (en) 2003-03-13
ATE254593T1 (de) 2003-12-15
EP1388534A3 (en) 2004-02-25
ES2207339T3 (es) 2004-05-16
KR20060118367A (ko) 2006-11-23
AU6051399A (en) 2000-04-26
JP2002526516A (ja) 2002-08-20
WO2000020370A1 (en) 2000-04-13
CA2346034A1 (en) 2000-04-13
EP1117628A1 (en) 2001-07-25
TW580494B (en) 2004-03-21
ZA200102635B (en) 2002-10-18
DE69912973T2 (de) 2004-07-22
US6147224A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
BR9914256A (pt) Derivados de ácido 2,4-pentadienóico tendo atividade seletiva para receptores de retinóide x (rxr)
KR870000289A (ko) 트리시클로데칸의 (메트)-아크릴산 유도체의 제조방법
BR9909423A (pt) Composição e método para produzir politioéteres tendo cadeias de metila pendentes
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
ATE270103T1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BR0307607A (pt) Derivados de carbonilamino como inibidores de histona desacetilase
DK1117648T3 (da) Tetrahydroquinolinderivater med selektiv virkning for retinoid X receptorer
DK0608847T3 (da) Carbocykliske sulfonamider som agonister eller antagonister for PGEZ
KR880003622A (ko) 카테콜유도체 및 그것을 함유하는 중추신경계 퇴행성 질환의 진행방지 및 치료제
BR9811691A (pt) ácidos éter-carboxìlicos como dispersantes de asfaltenos em óleos brutos.
EA200200098A1 (ru) Ароматические сложные эфиры для маркировки или мечения нефтепродуктов
RU94023250A (ru) 2,3-дигидро-1,4-бензодиоксин-5-ил-пиперазиновые производные, обладающие 5-нт1а-антагонистической активностью, способы их получения, фармкомпозиция на их основе, получение ее и способ лечения расстройств нервной системы
DE3665711D1 (de) Novel guanidinomethylbenzoic acid derivatives
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
AR016175A1 (es) Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.
ES2186322T3 (es) Derivados de acido perfluor-n-alcanosulfonico.
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
KR890000457A (ko) 티오펜 유도체
MX7122E (es) Procedimiento para la preparacion de derivados de tiometilpiridina
ATE272635T1 (de) Neue naphthyridinderivate.
BRPI9710537B8 (pt) derivados da eritromicina, composições farmacêuticas, bem como processo para preparação dos mesmos.
NO308249B1 (no) Nye indan-2-mercaptoacetylamid-disulfidderivater som er anvendbare som inhibitorer av enkefalinase
KR930702269A (ko) 포스포리파제 a2저해 물질
RU94031212A (ru) Производные тетразолуксусной кислоты, фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALLERGAN SALES, LLC (US)

B25A Requested transfer of rights approved

Free format text: ALLERGAN, INC (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI